ClinicalTrials.gg
CompletedNCT04520750VALO-2Updated Aug 29, 2024

VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita

A Phase 3 interventional study of PTX-022 in Pachyonychia Congenita, sponsored by Palvella Therapeutics, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-29.

Sponsored by Palvella Therapeutics, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2021, 5 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

VALO-2 is a multicenter, open-label extension (OLE) study enrolling patients with genotyped keratin mutations KRT6A, KRT6B and KRT16 who were previously treated with investigational PTX-022 during the VALO study. The purpose of the OLE study is to investigate long term exposure to investigational PTX-022 and evaluate safety and efficacy data. A sub-study is included to evaluate safety and efficacy of patients with genotyped keratin mutations of KRT6C and KRT17 not previously treated with investigational PTX-022.

02

Conditions studied

  • Pachyonychia Congenita
03

In context

Lead sponsor

Palvella Therapeutics, Inc. is the lead sponsor of 9 studies on the registry; 2 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Adult patients 18 years or older,
  • Previously completed the VALO protocol, or VALO-2 K6C/17 sub-study, and received meaningful benefit from PTX-022 as determined by the clinician.

Key Exclusion Criteria:

  • Any history of allergy or to sirolimus, or sirolimus-like medications or to PTX-022
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Open label treatment arm

    PTX-022 QTORIN

    Drug: PTX-022

Interventions

  • Safety and Efficacy of PTX-022 in the Treatment of Adults with Pachyonychia Congenita

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Time frame: 18 Months

  2. Changes in vital sign measurements from baseline

    Time frame: 18 months

  3. Changes in weight measurements from baseline

    Time frame: 18 months

  4. Changes in clinical laboratory measurements from baseline

    Time frame: 18 months

Secondary outcomes

  1. Patient Global Assessment of Activities Scale

    Time frame: 18 Months

  2. Pain at its worst as assessed by NRS

    Time frame: 18 months

  3. PROMIS Pain Interference Short 6A as assessed by likert scale

    Time frame: 18 months

  4. PROMIS Physical Function as assessed by likert scale

    Time frame: 18 months

  5. Patient Global Impression of Severity as assessed by likert scale

    Time frame: 18 months

  6. Clinician Global Impression of Severity as assessed by likert scale

    Time frame: 18 months

07

Study locations

4 sites
  • Arizona Research Center
    Phoenix, Arizona 85053, United States
  • Stanford University
    Palo Alto, California 94304, United States
  • Minnesota Clinical Study Center
    Fridley, Minnesota 55432, United States
  • University of Utah
    Murray, Utah 84107, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Jun 2021, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2020
First posted
Aug 20, 2020
StartActual
Sep 1, 2020
Primary completionActual
Jun 30, 2021
CompletionActual
Dec 15, 2022
Last update
Aug 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04520750
Lead sponsor
Palvella Therapeutics, Inc.
Responsible party
Sponsor
First posted
Aug 20, 2020
Start date
Sep 1, 2020
Primary completion
Jun 30, 2021
Completion
Dec 15, 2022
Last update
Aug 29, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus Topical Gel PTX-022

Start the discussion